Groupama Asset Managment Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Groupama Asset Managment increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,082 shares of the life sciences company’s stock after buying an additional 579 shares during the quarter. Groupama Asset Managment’s holdings in Illumina were worth $679,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its stake in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina in the fourth quarter valued at about $32,000. Assetmark Inc. boosted its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the fourth quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $48,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on ILMN. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Canaccord Genuity Group lowered their target price on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, March 11th. Robert W. Baird cut their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Finally, Guggenheim lowered their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $81.88 on Thursday. The stock’s 50-day simple moving average is $99.22 and its 200-day simple moving average is $125.82. The firm has a market capitalization of $12.97 billion, a PE ratio of -10.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a fifty-two week low of $77.54 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.